Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of AC-1204 vs AC-1202 in Healthy Volunteers
NCT02959710Phase 1Completed
- Sponsor
- Cerecin
- Start
- Nov 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tricaprilin in Alzheimer's disease (AD) (3 arms), sponsored by Cerecin. Primary endpoints: Total Ketones Pharmacokinetics (AUC, Cmax, Kel, T1/2, Tmax), Beta-hydroxybutyrate Pharmacokinetics (AUC, Cmax, Kel, T1/2, Tmax) and 1 more. Started Nov 2016; status: completed.
02
Drugs
tricaprilin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02959710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02959710.